BioSpace News Archive

Immunization is a public health and development success storey that saves millions of lives each year. By bolstering the body’s natural defences, vaccines reduce the chances of developing a disease. Vaccination helps avoid over 20 life-threatening diseases, helping people of all ages to live longer, healthier lives. Vaccines save lives of 2-3 million people per year from diseases such as diphtheria, tetanus, pertussis, influenza, and measles.

Rising prevalence of neurological diseases such as Alzheimer’s disease, Parkinson’s disease, and brain tumors is one of the major factors supporting the global market revenue growth

Increasing demand for high quality food products, rapidly expanding global population, and ongoing research activities on plant genomics are some key factors expected to drive global market growth

Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces that Management will participate in the upcoming investor events set out below:

The shift towards personalized medicine, increasing R&D investments, and growing disease variation, as well as prevalence, are favoring the market growth. There has been a rise in the prevalence of diseases due to which, pharmaceutical companies are increasing their R&D expenditure to launch new therapeutics in the market. That has, in turn, increased the clinical trial value and complexity.

Novocardia, a value-based cardiovascular disease care platform, has launched an innovative heart failure program that combines individualized health coaching and remote patient monitoring to improve the lives of heart failure patients and decrease the need for hospitalizations.

Mallinckrodt plc, (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced results of a retrospective, observational medical chart review subgroup analysis assessing real-world treatment outcomes among African Americans with advanced symptomatic sarcoidosis who initiated therapy with Acthar Gel (repository corticotropin injection).

The Sabin Vaccine Institute was awarded up to $6.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) for a clinical trial to evaluate the immunogenicity and safety of lower, fractional doses of registered COVID-19 vaccines used as a booster dose.

XOMA Corporation announced its Chairman and Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022, at 10:00 AM ET.

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that management will participate virtually in the H.C. Wainwright Global Investment Conference being held May 23-26, 2022.